Randomized controlled clinical trial of SFA002 for plaque-psoriasis
Latest Information Update: 08 Apr 2022
At a glance
- Drugs SFA 002 (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Sponsors SFA Therapeutics
Most Recent Events
- 28 Apr 2022 According to a SFA Therapeutics media release, following the phase 1b trial completion, SFA expects to finalize the SFA002 formulation and proceed to initiate this study.
- 08 Apr 2022 New trial record